Mirtazapine Does Not Treat EPS Symptoms
Mirtazapine is not a treatment for extrapyramidal symptoms (EPS) such as acute dystonia. In fact, mirtazapine itself can paradoxically cause movement disorders, though it may attenuate antipsychotic-induced EPS in specific experimental contexts.
Evidence-Based Treatment for EPS
Acute Dystonia
For acute dystonic reactions (sudden spastic muscle contractions affecting neck, eyes, or torso), anticholinergic or antihistaminic medications are the established first-line treatments 1, 2. These reactions can be life-threatening (e.g., laryngospasm) and require immediate intervention with agents like benztropine or diphenhydramine.
Drug-Induced Parkinsonism
Treatment options include 2:
- Lowering the antipsychotic dose
- Switching to another antipsychotic medication
- Adding an anticholinergic medication or amantadine
Akathisia
Management strategies include 2:
- Lowering the antipsychotic dose (if clinically feasible)
- Switching to another antipsychotic
- Adding a benzodiazepine
- Adding a beta-adrenergic blocking agent
Important Caveats About Mirtazapine
Mirtazapine can actually cause movement disorders itself, not treat them 3. A comprehensive literature review identified 179 cases of mirtazapine-associated movement disorders, including restless legs syndrome, tremors, akathisia, dystonia, and parkinsonism. These typically occurred within 7.54 days of starting mirtazapine, with management requiring drug withdrawal in most cases 3.
Experimental Context Only
While one preclinical study showed mirtazapine attenuated haloperidol-induced bradykinesia and catalepsy in rodents 4, this does not translate to clinical practice. The study suggested mirtazapine's noradrenergic and specific serotonergic antidepressant (NaSSA) properties might be superior to SSRIs when combining antidepressants with antipsychotics, but this relates to preventing EPS augmentation, not treating established EPS.
Risk of Serotonergic Antidepressants
Serotonergic antidepressants, including mirtazapine, have been associated with extrapyramidal reactions since 1958 5. These reactions typically occur within 30 days of treatment initiation or dose increase and can include akathisia, dystonia, dyskinesia, and parkinsonism.
Clinical Bottom Line
Use established EPS treatments: anticholinergics for acute dystonia, dose reduction or anticholinergics for parkinsonism, and beta-blockers or benzodiazepines for akathisia 1, 2. Mirtazapine has no role in treating EPS and may itself cause movement disorders requiring discontinuation 3.